Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes

9 Sept 2022

Abstract excerpt

Prostate cancer (PCa) is one of the leading causes of cancer-related deaths among men. Consequently, the identification of novel molecular targets for treatment is urgently needed to improve patients' outcomes. Our group recently reported that some elements of the cellular machinery controlling alternative-splicing might be useful as potential novel therapeutic tools against advanced PCa. However, the presence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Molecular Biology Techniques and Applications
Share to Prostate Cancer Treatment and Research
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36089245
DOI: 10.1016/j.trsl.2022.08.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genesPMID 36089245Read ↗

Alternative splicing in prostate cancer progression and therapeutic resistanceSemantic proximity Read ↗

Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancerSemantic proximity Read ↗

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancerSemantic proximity Read ↗

MBTPS2 acts as a regulator of lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancerSemantic proximity Read ↗

Dysregulated Alternative Splicing Landscape Identifies Intron Retention as a Hallmark and Spliceosome as a Therapeutic Vulnerability in Aggressive Prostate CancerSemantic proximity Read ↗

Large‐scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levelsSemantic proximity Read ↗

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)Semantic proximity Read ↗

Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.Semantic proximity Read ↗

The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissuesSemantic proximity Read ↗

MTA family of proteins in prostate cancer: biology, significance, and therapeutic opportunitiesSemantic proximity Read ↗

Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancerSemantic proximity Read ↗

Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.